BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet 2022;400:769-86. [PMID: 35964592 DOI: 10.1016/S0140-6736(22)01052-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 Buschulte K, Cottin V, Wijsenbeek M, Kreuter M, Diesler R. The world of rare interstitial lung diseases. Eur Respir Rev 2023;32. [PMID: 36754433 DOI: 10.1183/16000617.0161-2022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Yao Y, Li Y, Zhu X, Zhao C, Yang L, Huang X, Wang L. The emerging role of the piRNA/PIWI complex in respiratory tract diseases. Respir Res 2023;24:76. [PMID: 36915129 DOI: 10.1186/s12931-023-02367-9] [Reference Citation Analysis]
3 Zhou P, Shen Q, Zhou S, Ouyang X, Guo T, Song M, Guo W, Zhang Y, Peng H. The prognostic role of C-reactive protein to albumin ratio and anti-MDA5 antibody-positive in idiopathic inflammatory myopathy: a retrospective study. Sci Rep 2023;13:3863. [PMID: 36890164 DOI: 10.1038/s41598-023-30595-y] [Reference Citation Analysis]
4 Adegunsoye A, Freiheit E, White EN, Kaul B, Newton CA, Oldham JM, Lee CT, Chung J, Garcia N, Ghodrati S, Vij R, Jablonski R, Flaherty KR, Wolters PJ, Garcia CK, Strek ME. Evaluation of Pulmonary Fibrosis Outcomes by Race and Ethnicity in US Adults. JAMA Netw Open 2023;6:e232427. [PMID: 36897590 DOI: 10.1001/jamanetworkopen.2023.2427] [Reference Citation Analysis]
5 Kumazoe M, Ogawa F, Hikida A, Shimada Y, Yoshitomi R, Watanabe R, Onda H, Fujimura Y, Tachibana H. Plant miRNA osa-miR172d-5p suppressed lung fibrosis by targeting Tab1. Sci Rep 2023;13:2128. [PMID: 36746980 DOI: 10.1038/s41598-023-29188-6] [Reference Citation Analysis]
6 Cerro Chiang G, Parimon T. Understanding Interstitial Lung Diseases Associated with Connective Tissue Disease (CTD-ILD): Genetics, Cellular Pathophysiology, and Biologic Drivers. Int J Mol Sci 2023;24. [PMID: 36768729 DOI: 10.3390/ijms24032405] [Reference Citation Analysis]
7 de la Hoz RE, Johannson KA. World Trade Center Health Program best practices for the diagnosis and treatment of fibrosing interstitial lung diseases. Arch Environ Occup Health 2023;:1-4. [PMID: 36632789 DOI: 10.1080/19338244.2023.2166007] [Reference Citation Analysis]
8 Wijsenbeek MS, Brusselle GG. Risk Stratifying Interstitial Lung Abnormalities to Guide Early Diagnosis of Interstitial Lung Diseases. Am J Respir Crit Care Med 2023;207:9-11. [PMID: 36170647 DOI: 10.1164/rccm.202209-1817ED] [Reference Citation Analysis]
9 Hata K, Yanagihara T, Matsubara K, Kunimura K, Suzuki K, Tsubouchi K, Eto D, Ando H, Uehara M, Ikegame S, Baba Y, Fukui Y, Okamoto I. Mass cytometry identifies characteristic immune cell subsets in bronchoalveolar lavage fluid from interstitial lung diseases. Front Immunol 2023;14:1145814. [PMID: 36949950 DOI: 10.3389/fimmu.2023.1145814] [Reference Citation Analysis]
10 Holland AE, Glaspole I. Lockdown as the mother of invention: disruptive technology in a disrupted time. Lancet Respir Med 2023;11:9-11. [PMID: 36206781 DOI: 10.1016/S2213-2600(22)00291-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ohta R, Murakami K, Tanaka Y, Mishiro T, Sano C. Difficulty in Diagnosing Anti-neutrophil Cytoplasmic Antibody-Related Vasculitis With Interstitial Pneumonia and in Ascertaining the Cause of Associated Hematochezia: A Case Report. Cureus 2023;15:e34091. [PMID: 36843755 DOI: 10.7759/cureus.34091] [Reference Citation Analysis]
12 Kuwana M, Bando M, Kawahito Y, Sato S, Suda T, Kondoh Y; CTD-ILD Delphi Collaborators. Identification and management of connective tissue disease-associated interstitial lung disease: evidence-based Japanese consensus statements. Expert Rev Respir Med 2023;17:71-80. [PMID: 36786105 DOI: 10.1080/17476348.2023.2176303] [Reference Citation Analysis]
13 Pyo JY, Lee LE, Park YB, Lee SW. Comparison of the 2022 ACR/EULAR Classification Criteria for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Previous Criteria. Yonsei Med J 2023;64:11-7. [PMID: 36579374 DOI: 10.3349/ymj.2022.0435] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Tezcan ME, Kasman SA. GROUND GLASS OPACITIES: SIGN OF CAUTION IN TYPICAL INTERSTITIAL PNEUMONIA. CAJMHE 2022;3:241-244. [DOI: 10.47316/cajmhe.2022.3.4.03] [Reference Citation Analysis]
15 Drakopanagiotakis F, Stavropoulou E, Tsigalou C, Nena E, Steiropoulos P. The Role of the Microbiome in Connective-Tissue-Associated Interstitial Lung Disease and Pulmonary Vasculitis. Biomedicines 2022;10. [PMID: 36551951 DOI: 10.3390/biomedicines10123195] [Reference Citation Analysis]
16 Papiris SA, Kannengiesser C, Borie R, Kolilekas L, Kallieri M, Apollonatou V, Ba I, Nathan N, Bush A, Griese M, Dieude P, Crestani B, Manali ED. Genetics in Idiopathic Pulmonary Fibrosis: A Clinical Perspective. Diagnostics (Basel) 2022;12. [PMID: 36552935 DOI: 10.3390/diagnostics12122928] [Reference Citation Analysis]
17 Shao G, Hawle P, Akbari K, Horner A, Hintenberger R, Kaiser B, Lamprecht B, Lang D. Clinical, imaging, and blood biomarkers to assess 1-year progression risk in fibrotic interstitial lung diseases—Development and validation of the honeycombing, traction bronchiectasis, and monocyte (HTM)-score. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1043720] [Reference Citation Analysis]
18 Egea-Zorrilla A, Vera L, Saez B, Pardo-Saganta A. Promises and Challenges of Cell-Based Therapies to Promote Lung Regeneration in Idiopathic Pulmonary Fibrosis. Cells 2022;11:2595. [PMID: 36010671 DOI: 10.3390/cells11162595] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]